Recent advances in immunotherapy have fundamentally changed the landscape of cancer
treatment by leveraging the specificity and selectivity of the adaptive immune system to kill …

Simple Summary Many patients with the aggressive cancer diffuse large B-cell lymphoma
(DLBCL) still respond poorly to treatment and suffer from relapsed or refractory disease. The …

Implementation of therapeutic in vivo gene editing using CRISPR/Cas relies on potent
delivery of gene editing tools. Administration of ribonucleoprotein (RNP) complexes …

Introduction In epithelial cancers, truncated O-glycans, such as the Thomson-nouveau
antigen (Tn) and its sialylated form (STn), are upregulated on the cell surface and …

Background: Head and neck squamous cell carcinomas are the sixth most common
malignant tumors worldwide. Tongue squamous cell carcinoma is a common malignant …

Prime editing is a novel genome editing technology that allows a wide range of tailored
genomic alterations. Prime editing does not involve homologous recombination, but suffers …

The frontline therapy R‐CHOP for patients with diffuse large B‐cell lymphoma (DLBCL) has
remained unchanged for two decades despite numerous Phase III clinical trials investigating …

Simple Summary Clustered regularly interspaced short palindromic repeats (CRISPR) were
discovered in prokaryotes, and the technology can also be used to edit the genome in …

A significant proportion of breast cancers are driven by ErbB2/Her2 oncoprotein that they
overexpress. These malignancies are typically treated with various ErbB2-targeted drugs …

Introduction Diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell
lymphoma (PMBCL) are aggressive histological subtypes of non-Hodgkin's lymphoma …